Connect with us

Market

Are Cannabis Stocks Part Of Your Portfolio? Oxis International (OTCMKTS: OXIS), OSL Holdings (OTCMKTS: OSLH), Medican Enterprises (OTCMKTS: MDCN)

Published

on

This year has gotten off to a much stronger start for cannabis stocks.  For those who remember 2014’s launch of the green rush, there was much more uncertainty as to the direction and overall future that this market would have.  But as more states have legalized recreational and medicinal marijuana, the path seems clearer and in turn, new business opportunities have begun to flourish.  It’s not just dispensaries and growing operations that are bringing attention to the space.  Now there are companies focusing on multiple aspects of the market.  Companies like Oxis International  (OTCMKTS: OXIS), OSL Holdings (OTCMKTS: OSLH) and Medican Enterprises (OTCMKTS: MDCN) which focus on health sciences.  This has been a much more popular industry segment as of late, which has encompassed traditional biotechnology as well as a more lifestyle branded use.

 OXIS International Inc. is one of the companies focused on utilizing biotechnology in the treatment of cancer as well as therapy development and commercialization targeting triple-negative breast cancer.  This month Oxis released several key announcements including one on May 6th OXIS with the addition of Cassian Yee, M.D to its scientific advisory board and another on May 12th with Oxis bringing onn The Emmes Group to help with its strategic business and therapeutic development initiatives.  Over the last 10 days, the stock has seen prices as high as $0.0347 and as low as $0.0265 with a close of $0.028 on Thursday.

 OSL Holdings is more of a multi pronged organization and medical/recreational cannabis is one of these prongs.  The company entered the space through its medical division.  According to the Company, OSL Medical Services is a development platform centered on the progress and financing of indoor gardens and cultivation facilities, production technologies, and merchandise and operational services for businesses in the herbal and supplement industry.  The Company recently announced a joint venture with one of the more prominent figureheads in popular cannabis culture, Cheryl Shuman. “This first joint venture with OSL is incredibly exciting!   As the founder of the Beverly Hills Cannabis Club, we were the first in the industry to produce luxurious celebrity events and mixers for the affluent.   Now, together with the dream team at OSL, we can begin to corner the luxury market by becoming the “connector” of influencers in cannabis and culture, both here in the U.S. and abroad. I’m thrilled to be on this journey with OSL,” said Cheryl Shuman.

 OSL Holdings share price has increased by as much as 1,342% since the end of March.

 Medican Enterprises (MDCN) announced earlier this month that the Company has closed on its acquisition of TWYNS, a company that provides branding services for enterprises in the Cannabidiol or “CBD” business. According to Medican, transaction is valued at approximately $1 million all in stock and is expected to add approximately $400,000 to Medican’s annual revenues.  To those who are unfamiliar, unlike medical cannabis, which is produced generally from strains of cannabis designed to deliver high levels of THC, CBD products can be extracted from industrial hemp, the high CBD, low THC strain used to produce textiles, ropes, resins, paper and other industrial materials.

 Ken Williams, CEO of Medican Enterprises stated, “The model is Coca-Cola’s very successful bottling distributing arrangement. We believe that cannabis will be a cottage industry for the foreseeable future, with each regulated jurisdication demanding fees and licenses. TWYNS will provide local growers, product manufacturers and distributors with a reliable ‘seal of approval’ that ensures quality and provides the consumer with a reliable benchmark.”

About marijuanastocks.com

 MarijuanaStocks.com is the leading web destination for all things cannabis. Investors can find marijuana related financial, medical, legal, and social news anytime day or night. Writers are invited to submit cannabis related articles for publication.

 Legal Disclaimer

 Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. MAPH Enterprises LLC which owns www.MarijuanaStocks.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release.

MAPH Enterprises LLC, which owns www.MarijuanaStocks.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. MAPH Enterprises LLC,  which owns www.MarijuanaStocks.com, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two.

Contact Information:

marijuanastocks.com

800-539-4313
pr@marijuanastocks.com


SOURCE:
MarijuanaStocks.com

Biotech

CytoDyn Inc (OTCMKTS:CYDY) Regains Momentum After The Big Announcement

Published

on

By

Now that the market seems to be coming back into his elements, it could be time for investors to start looking into penny stocks more closely. These stocks may often be risky, but if one makes the right choice, then the rewards could be enormous. One penny stock that could be put into the watch list at this point in time is that of CytoDyn Inc (OTCMKTS:CYDY).

The late-stage biotechnology company, which is developing the coronavirus medicine leronlimab, announced last week that it had filed a comprehensive application for uplisting on NASDAQ. The company announced that it believes that its application satisfies the myriad listing requirements of the NASDAQ Capital Market.

The Chief Executive Officer and President of the company Nader Pourhassan stated that while it is true that the entire process is expected to take many weeks, CytoDyn is hopeful of success in this matter.

He went on to state that a listing on NASDAQ will not only provide shareholders with more liquidity but also give CytoDyn much bigger access to fresh capital. It is a significant development for the company, and the market participants realized it as well. After the announcement was made, the stock rallied by as much as 50%. Investors could do well to keep an eye on the stock this week.

While the rally following this announcement was a welcome relief for the company, it is important to point out that earlier on in the week, the stock has fallen considerably following a setback. Last Monday, the company announced that the United States Food and Drug Administration handed CytoDyn a refusal to file a letter with regards to the usage of leronlimab to treat HIV.

However, at the same time, investors should be noted that the company did announce that it is confident of furnishing the agency with all the further details that have been demanded. It is one of the penny stocks that have performed remarkably well this year so far, and investors could keep an eye on it.

Continue Reading

Market

These 3 Pot Stocks Are Up Big Since May: What’s the Buzz?

Published

on

By

Over the course of the past year or so, pot stocks had generally struggled, but during the past month, those stocks have recovered nicely. The stock market suffered a historic fall due to the economic turmoil caused by the coronavirus pandemic. It is believed that investors who are looking for value have descended on the beaten-down pot stocks. On the flip side, these stocks could also have been identified as defensive plays in an uncertain market environment.

That being said, it should be noted that despite the gains recorded by many stocks, most of those stocks are still considerably lower than the all-time highs. In such a situation, it could be worthwhile for investors to take a closer look at some of the strongest and more stable cannabis companies in the industry. Here is a look at three pot stocks that made significant moves in May and could be tracked by investors at this point.

1. HEXO Stock Jumps Ahead of Earnings

HEXO Corp (TSX:HEXO) (NYSE:HEXO) is one of those cannabis companies which have had a particularly tough time over the past year or so. However, the stock has emerged as one of the bigger gainers among pot stocks in recent trading sessions. The Hexo stock has gained as much as 120% over the course of the past month. The company is all set to release its financial results for the fiscal third quarter on Thursday, and hence, it could be a big week for the stock.

The recent surge in the Hexo stock may have come as a major boost to investors, but it should be noted that over the past year, it recorded considerable losses. The beaten-down nature of the stock may have contributed to the stock becoming more attractive for investors. However, the trajectory of the Hexo stock in the near term is going to depend a lot on its third-quarter earnings.

The company had made a loss of $298 million in the previous quarter, and while it is almost certain that it is going to make a loss again, the size of the loss is going to be keenly watched. Additionally, any writedowns are also going to be harmful to the stock. Investors should also keep an eye on sales growth.

2 Organigram gains Momentum on Value Buying

Organigram Holdings (TSX:OGI) (NASDAQ:OGI) is another pot stock that has made significant gains in the past month. Since May 13, the stock has gained as much as 80%. In April, the company announced its fiscal second-quarter results, but it had been a disappointment.

Revenues dropped by 13.7% year on year to hit CA$23.2 million, and losses widened to CA$6.8 million from CA$6.4 million in the prior-year period. However, one significant cause for optimism for Organigram investors is the fact that in the second quarter, cannabis 2.0 products made up as much as 13% of its revenue. That has opened up a whole new opportunity for the company.

Wholesale cannabis revenue made up 24% of the net, and that is again a new source of revenue. The company blamed the lower volumes of flower as well as cannabis oil for the drop in sales. Organigram reported cash and cash equivalents of CA$41.1 million as of February 29. Considering the fact that it has burned CA$25 million in the past six months, investors should not use that the cash balance does not paint a pretty picture.

3 Aphria Recovers Following Solid Earnings

Aphria (TSX:APHA) (NYSE:APHA), on the other hand, managed to perform relatively well in its fiscal third quarter. The net sales rose by as much as 19.7% sequentially to hit CA$144.4 million, and more importantly, the company also managed to record a profit for the third time in four quarters. On top of that, it should be noted that although the Canadian cannabis company spends CA$124.4 million on its operations in the nine months trailing that quarter, it still reported a cash balance of CA$515 million.

The performance seems to have buoyed market participants as well, and the stock has rallied by as much as 75% since the middle of May. One of the most important things that investors are going to be looking into is whether Aphria is going to be able to maintain its profitability.

However, due to the turmoil caused by the coronavirus pandemic, it might prove difficult. That being said, it should be noted that the pandemic is going to have an equally damaging effect across the sector.

Continue Reading

Market

ConforMIS Inc (NASDAQ: CFMS): Premium Members Made A Quick 65% Profit In Just 1 week

Published

on

Well, as we know there are two types of person in the stock market one is trader and another is investor. Investors tend to put money for longer time, while traders make short term bets. We know, its not at all easy to make money in the short term especially in the equity markets. However, premium members at Traders Insights are making awesome money on our calls on our swing trading calls. WE ARE OFFERING A SPECIAL 7-Day Trial Period at Just $5 (so that everybody can make money with us and join us if satisfied). Register Here http://tradersinsights.com/pricing/
JOIN US NOW: For Details Contact us at info@tradersinsights.com

Or You can send me a friend request on facebook here https://www.facebook.com/sebastian.gomestradersinsights

Now let me show you how we made quick 43% in just 1-week which was posted to our premium members:-

We told our members in facebook private group to buy ConforMIS Inc (NASDAQ: CFMS) yesterday (march 13th) at $1.36. Now look at the price of the stock – its up 65% at $2.25 from our buy price. This is how easy money they made. If you had invested $5,000 in CFMS, it could had been moved up to $8,250. It’s not yet late, join us at info@tradersinsights.com

Continue Reading
Advertisement

Trending